Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Rating Changes as of May 17, 2018

May 17, 2018 - By Matthew Richard

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

Total analysts of 2 have positions in Collegium Pharmaceutical (NASDAQ:COLL) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 29, 2017 according to StockzIntelligence Inc Collegium Pharmaceutical has 6 analyst reports. On Monday, February 12 the rating was maintained by Piper Jaffray with “Buy”. On Tuesday, January 23 the rating was maintained by Piper Jaffray with “Buy”. On Wednesday, November 29 the company was maintained by Piper Jaffray. On Sunday, February 11 the firm has “Buy” rating by Jefferies given. On Thursday, December 7 the rating was maintained by Piper Jaffray with “Buy”. In Thursday, December 14 report Piper Jaffray maintained the stock with “Buy” rating. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain

COLL hit $25.1 during the last trading session after $0.54 change.Currently Collegium Pharmaceutical, Inc. is uptrending after 133.98% change in last May 17, 2017. COLL has 186,789 shares volume. COLL outperformed by 122.43% the S&P 500.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is valued at $829.40 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Currently it has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news released recently go to: Seekingalpha.com, Globenewswire.com, Globenewswire.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “FDA OKs first non-opioid treatment for opioid withdrawal” released on May 16, 2018, “Collegium Reports First Quarter Financial Results and Provides Corporate Update” on May 09, 2018, “Collegium to Present at the Deutsche Bank Health Care Conference” with a publish date: May 02, 2018, “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” and the last “Collegium Pharmaceutical’s (COLL) CEO Michael Heffernan on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.